Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Organogenesis Holdings Inc (NASDAQ: ORGO) closed at $4.67 in the last session, up 2.41% from day before closing price of $4.56. In other words, the price has increased by $2.41 from its previous closing price. On the day, 0.95 million shares were traded. ORGO stock price reached its highest trading level at $4.73 during the session, while it also had its lowest trading level at $4.55.
Ratios:
We take a closer look at ORGO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.35 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 141.70. For the most recent quarter (mrq), Quick Ratio is recorded 3.35 and its Current Ratio is at 3.69. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Lake Street on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5.
On February 07, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.Morgan Stanley initiated its Equal-Weight rating on June 15, 2023, with a $5 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 04 ’25 when Driscoll Michael Joseph bought 25,000 shares for $5.08 per share.
Driscoll Michael Joseph sold 25,000 shares of ORGO for $127,535 on Mar 04 ’25. The Director now owns 166,879 shares after completing the transaction at $5.10 per share. On Dec 13 ’24, another insider, Gillheeney Gary S., who serves as the President and CEO of the company, sold 55,615 shares for $3.36 each. As a result, the insider received 186,866 and left with 3,044,779 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORGO now has a Market Capitalization of 592286784 and an Enterprise Value of 622138176. As of this moment, Organogenesis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 833.93, and their Forward P/E ratio for the next fiscal year is 25.02. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.23 while its Price-to-Book (P/B) ratio in mrq is 2.23. Its current Enterprise Value per Revenue stands at 1.291 whereas that against EBITDA is 16.141.
Stock Price History:
The Beta on a monthly basis for ORGO is 1.86, which has changed by 0.987234 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, ORGO has reached a high of $6.71, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 4.56%, while the 200-Day Moving Average is calculated to be 33.96%.
Shares Statistics:
According to the various share statistics, ORGO traded on average about 2.05M shares per day over the past 3-months and 1587110 shares per day over the past 10 days. A total of 125.73M shares are outstanding, with a floating share count of 64.38M. Insiders hold about 49.24% of the company’s shares, while institutions hold 47.81% stake in the company. Shares short for ORGO as of 1744675200 were 10205835 with a Short Ratio of 4.97, compared to 1741910400 on 8615328. Therefore, it implies a Short% of Shares Outstanding of 10205835 and a Short% of Float of 34.089999999999996.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
As of right now, 1.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.03, with high estimates of $0.03 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.16 and $0.16 for the fiscal current year, implying an average EPS of $0.16. EPS for the following year is $0.28, with 1.0 analysts recommending between $0.28 and $0.28.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $90.77M. It ranges from a high estimate of $93.8M to a low estimate of $87.7M. As of the current estimate, Organogenesis Holdings Inc’s year-ago sales were $109.98MFor the next quarter, 3 analysts are estimating revenue of $102.17M. There is a high estimate of $115.1M for the next quarter, whereas the lowest estimate is $94.7M.
A total of 4 analysts have provided revenue estimates for ORGO’s current fiscal year. The highest revenue estimate was $508.6M, while the lowest revenue estimate was $450.5M, resulting in an average revenue estimate of $488.25M. In the same quarter a year ago, actual revenue was $482.04MBased on 3 analysts’ estimates, the company’s revenue will be $549.3M in the next fiscal year. The high estimate is $584.91M and the low estimate is $528M.
